journal
https://read.qxmd.com/read/38655566/magnitude-of-thrombocytopenia-and-associated-factors-among-pregnant-women-attending-the-antenatal-care-service-unit-of-wachemo-university-nigist-ellen-mohammed-comprehensive-specialized-hospital-hosanna-southern-ethiopia
#1
JOURNAL ARTICLE
Dembelo Tirago, Tilahun Yemane, Edosa Tadasa
BACKGROUND: Thrombocytopenia is the second most common hematological disorder in pregnancy after anemia worldwide and affects 7-8% of all pregnancies. Pregnant women with thrombocytopenia have complications of excessive bleeding during or after childbirth, exudation at the cesarean section, and neonatal thrombocytopenia. Therefore, the main aim of this study was to assess the magnitude of thrombocytopenia and its associated factors among pregnant women attending the Antenatal Care Service Unit of Wachemo University Nigist Ellen Mohammed Comprehensive Specialized Hospital Hosanna, Southern Ethiopia...
2024: Advances in Hematology
https://read.qxmd.com/read/38533292/prevalence-of-stroke-in-individuals-with-sickle-cell-disease-pre-and-during-hydroxyurea-uses-a-descriptive-cross-sectional-study-in-tanzania
#2
JOURNAL ARTICLE
Belinda Nestory Moshi, Erick G Philipo, Nancy F Kileo, Joseph Matobo, Emili Yondu, Dionis Ikunda, Daniel Kandonga, Koga M Luhulla, Manase Kilonzi
Sickle cell disease (SCD) is an inherited blood disorder that leads to a variety of complications, including stroke. The use of hydroxyurea (HU) is reported to lessen the frequency and burden of stroke in SCD patients. However, less is known about the prevalence of stroke in SCD patients pre- and during the use of HU in sub-Saharan African (SSA) countries. Therefore, the study assessed stroke prevalence before and during uses of hydroxyurea among SCD patients in Tanzania. A hospital-based descriptive cross-sectional study was conducted at the sickle cell clinics in Dar es Salaam, Tanzania, from April 2023 to May 2023...
2024: Advances in Hematology
https://read.qxmd.com/read/38524403/challenges-and-outcomes-of-the-first-stem-cell-transplant-program-in-tanzania-east-africa
#3
JOURNAL ARTICLE
Stella Rwezaula, Mbonea Yonazi, Amey Panchal, Ashish Dhoot, Jemy Mathew, Sonu Tony, Sandeep Rao, Peter Muhoka, Samira Mahfudh, Neema Budodi, Mabula Kasubi, Flora Ndobho, Helena Kakumbula, Koga Luhulla, Linda Kapesa, Heri Tungaraza, Sarah Nyagabona, Agnes Shayo, Felister Seleki, Janeth Mtenga, Khadija Mwamtemi, Musa Suko, Isaac Mbughi, Mariana Shirima, Alfayo Mkisi, Rahma Ally, Malselina Kyaruzi, Else Arola Myaka, Johari Matiku, Mariam Nyamwaira, Saranya Nair, Aswathy Asokan, Goutham Kumar, Raj Badavath, Hedwiga Swai, Lawrence Museru, B S Ajaikumar, Deogratius Beda, Sachin Jadhav
INTRODUCTION: Due to the significant resources involved in creating HSCT programs there is a significant disparity in the availability of this treatment modality between the developed and developing countries. This manuscript details the process and the outcomes of the first HSCT program in East Africa which was started at Muhimbili National Hospital (MNH) in Dar-es-Salaam, Tanzania. MATERIALS AND METHODS: Information and data were collected on the processes which had been implemented for starting the HSCT program at MNH...
2024: Advances in Hematology
https://read.qxmd.com/read/38500844/the-association-of-anticoagulation-intensity-with-outcomes-in-hospitalized-covid-19-patients
#4
JOURNAL ARTICLE
Rena Zheng, Alexandra Solomon, Madeline DiLorenzo, Iniya Rajendran, Joseph Park, Vrushali Dhongade, Michael A Garcia, Robert T Eberhardt, John Mark Sloan, Janice Weinberg, Elizabeth S Klings
Venous thromboembolism (VTE) risk is increased in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A key question was whether increased intensity of anticoagulation would help prevent VTE and improve patient outcomes, including transfer to the intensive care unit (ICU) and mortality. At the start of the coronavirus disease-19 (COVID-19) pandemic, our institution, Boston Medical Center, instituted a VTE risk stratification protocol based on patients' initial D-dimer levels, medical history, and presence of thrombosis to determine whether they should receive standard-dose prophylaxis, high-dose prophylaxis, or therapeutic anticoagulation...
2024: Advances in Hematology
https://read.qxmd.com/read/38435839/the-role-of-methylation-in-chronic-lymphocytic-leukemia-and-its-prognostic-and-therapeutic-impacts-in-the-disease-a-systematic-review
#5
REVIEW
Sevastianos Chatzidavid, Christina-Nefeli Kontandreopoulou, Nefeli Giannakopoulou, Panagiotis T Diamantopoulos, Christos Stafylidis, Marie-Christine Kyrtsonis, Maria Dimou, Panayiotis Panayiotidis, Nora-Athina Viniou
Epigenetic regulation has been thoroughly investigated in recent years and has emerged as an important aspect of chronic lymphocytic leukemia (CLL) biology. Characteristic aberrant features such as methylation patterns and global DNA hypomethylation were the early findings of the research during the last decades. The investigation in this field led to the identification of a large number of genes where methylation features correlated with important clinical and laboratory parameters. Gene-specific analyses investigated methylation in the gene body enhancer regions as well as promoter regions...
2024: Advances in Hematology
https://read.qxmd.com/read/38375212/an-approach-to-the-investigation-of-thrombocytosis-differentiating-between-essential-thrombocythemia-and-secondary-thrombocytosis
#6
JOURNAL ARTICLE
Ala Almanaseer, Benjamin Chin-Yee, Jenny Ho, Alejandro Lazo-Langner, Laila Schenkel, Pratibha Bhai, Bekim Sadikovic, Ian H Chin-Yee, Cyrus C Hsia
BACKGROUND: Thrombocytosis is a common reason for referral to Hematology. Differentiating between secondary causes of thrombocytosis and essential thrombocythemia (ET) is often clinically challenging. A practical diagnostic approach to identify secondary thrombocytosis could reduce overinvestigation such as next generation sequencing (NGS) panel. METHODS AND RESULTS: All adult patients with thrombocytosis (≥450 × 109 /L) who underwent molecular testing at a single tertiary care centre between January 1, 2018 and May 31, 2021 were evaluated...
2024: Advances in Hematology
https://read.qxmd.com/read/38375211/clinical-profile-and-treatment-of-multiple-myeloma-at-a-tertiary-hospital-in-kenya-a-five-year-retrospective-review
#7
JOURNAL ARTICLE
Wanjiku Gichuru, Nicholas A O Abinya, Andrew Odhiambo, Fredrick C F Otieno, Simon Harrison, Matilda Ong'ondi
BACKGROUND: Multiple myeloma (MM) is a chronic B-cell malignancy that involves proliferation of neoplastic clonal plasma cells in the bone marrow with circulating monoclonal immunoglobulins or constituent chains in serum or urine or both. It is a rare cancer with a lifetime risk of 0.76% and an age-adjusted incidence rate of 2.5-7.2 per 100,000 in high-income countries. There is a paucity of local data on the morbidity and treatment of MM. METHODS: This was a single-centre descriptive retrospective study at the Kenyatta National Hospital (KNH)...
2024: Advances in Hematology
https://read.qxmd.com/read/38362014/presence-and-onset-of-chronic-kidney-disease-as-a-factor-involved-in-the-poor-prognosis-of-patients-with-essential-thrombocythemia
#8
JOURNAL ARTICLE
Yoshinori Hashimoto, Hiromi Omura, Takayuki Tanaka
Chronic kidney disease (CKD) is an important risk factor for cardiovascular disease, thrombosis, and all-cause death. However, few studies have examined the association between CKD and the prognosis of patients with essential thrombocythemia (ET). We collected ET patients who met the WHO classification 2017 and performed a retrospective clinical study to clarify the association between the presence and onset of CKD and prognosis. Of 73 patients who met the diagnostic criteria, 21 (28.8%) had CKD at the time of ET diagnosis...
2024: Advances in Hematology
https://read.qxmd.com/read/38356903/homozygous-sickle-cell-disease-after-age-of-40-follow-up-of-a-cohort-of-209-patients-in-senegal-west-africa
#9
JOURNAL ARTICLE
Moussa Seck, Maureen Adéniké Dabo, Elimane Seydi Bousso, Mohamed Keita, Sokhna Aïssatou Touré, Sérigne Mourtalla Guèye, Blaise Félix Faye, Fatma Dieng, Saliou Diop
OBJECTIVES: The aim of this study was to describe the morbidity and mortality of homozygous sickle cell disease after the age of 40. METHODS: This was a cohort study of 209 patients followed from 1994 to 2022. All hemoglobin electrophoresis-confirmed SS sickle cell patients over 40 years were included. A descriptive study of epidemiological, diagnostic, therapeutic, and evolutionary data was used to assess morbidity and mortality. RESULTS: Sex ratio (M/F) was 0...
2024: Advances in Hematology
https://read.qxmd.com/read/38178972/anemia-prevalence-and-risk-factors-in-two-of-ethiopia-s-most-anemic-regions-among-women-a-cross-sectional-study
#10
JOURNAL ARTICLE
Gebru Gebremeskel Gebrerufael, Bsrat Tesfay Hagos
BACKGROUND: In Sub-Saharan African (SSA) nations, including Ethiopia, anemia is a significant public health issue. Ethiopia has continued to bear the enormous burden of anemia infections. Over time, the prevalence of anemia has significantly increased in Ethiopia. In addition, there is a paucity of literature and regional variations in the pace of increment expansion. Therefore, the primary goal of this study was to evaluate the prevalence of anemia and risk factors among women in Ethiopia's two most anemic regions...
2023: Advances in Hematology
https://read.qxmd.com/read/38116392/retrospective-study-to-reduce-blood-transfusion-waste-in-remote-island-healthcare-settings
#11
JOURNAL ARTICLE
Takamitsu Sakamoto, Hiroyuki Mizuta, Naohisa Niiro, Teruyoshi Amagai
BACKGROUND: Tokunoshima is a remote island in the Amami Islands, 470 km southwest of the Kagoshima mainland. It has a population of 23,000 and consists of three towns: Tokunoshima, Isen, and Amagi. Three medical institutions on the island are responsible for blood transfusion medicine, but there is no blood stockpiling station on the island, and blood is stockpiled in each of the hospitals. Although Tokunoshima Tokushukai Hospital is responsible for 70% of transfusion medicine on Tokunoshima, it is difficult to maintain a sufficient amount of blood in stock considering disposal...
2023: Advances in Hematology
https://read.qxmd.com/read/38094101/novel-pharmacological-treatment-options-of-steroid-refractory-graft-versus-host-disease
#12
REVIEW
Iuliia Kovalenko, Tabinda Saleem, Mitali Shah, Sara Seyedroudbari, Konstantin Golubykh, Rimsha Ali, Taaha Mirza, Babray Laek, Ahsan Wahab, Asmi Chattaraj, Ekaterina Proskuriakova, Chandi Garg, Rafiullah Khan
BACKGROUND: Graft-versus-host disease (GVHD) is a potentially fatal complication of allogeneic hematopoietic stem cell transplant. The mainstay of treatment is corticosteroids, which are ineffective in 30-50% of cases. Steroid-refractory GVHD (SR-GVHD) confers a poor prognosis, with high mortality rates despite appropriate therapy. While there is no reliable treatment for SR-GVHD, a variety of novel therapeutic options are slowly emerging and have yet to be examined simultaneously. OBJECTIVES: This review evaluates the potential of novel therapeutic options, as well as their efficacy and safety, for the treatment of SR-GVHD...
2023: Advances in Hematology
https://read.qxmd.com/read/38029004/prognostic-factors-and-outcome-of-patients-with-adult-acute-lymphoblastic-leukemia-treated-with-the-hyper-cvad-regimen-a-retrospective-study
#13
JOURNAL ARTICLE
Zahra Malakoutikhah, Farzaneh Ashrafi, Ali Derakhshandeh
AIM: The Hyper-CVAD regimen has shown promising results for adult patients with acute lymphoblastic leukemia (ALL), as designed by the MD Anderson Cancer Center (MDACC). This treatment has resulted in a complete remission rate of 92% and a 5-year overall survival of 38%. However, given the diversity of patient demographics and institutional methods, outcomes may differ between various institutions. This study will compare the outcome of adult ALL patients treated with the Hyper-CVAD regimen in Iran with those obtained in the original series presented at the MDACC...
2023: Advances in Hematology
https://read.qxmd.com/read/38029003/association-between-blood-group-and-change-in-coagulation-factors-in-plasma-preparations-for-transfusion-purpose-at-kisii-teaching-and-referral-hospital
#14
JOURNAL ARTICLE
Collince Odiwuor Ogolla, Benson Nyanchongi, Rodgers Norman Demba
BACKGROUND: Blood component therapy helps in managing patients with reduced hematopoiesis, elevated peripheral destruction of cells, and generalized blood loss (bleeding). Increased prevalence of arterial and venous thrombotic disease linked to the impact of ABO blood group on plasma levels of coagulation glycoprotein is demonstrated by blood group non-O persons. OBJECTIVE: This study had a main objective of determining the association between blood group and change in coagulation factors in plasma preparation for transfusion purpose...
2023: Advances in Hematology
https://read.qxmd.com/read/37822646/exploring-hematological-parameters-and-their-prognostic-value-in-adult-covid-19-patients-insights-from-mogadishu-somalia
#15
JOURNAL ARTICLE
Abdirasak Sharif Ali Mude, Abd Elhadi Mohamed Agena Musa
There were no data on SARS-CoV-2 and hematology in Mogadishu, Somalia, despite the fact that many prior investigations of SARS-CoV-2 and hematology have already been conducted in many different parts of the world. As a result, this study aimed to assess hematological changes in COVID-19-infected patients at some selected hospitals in Mogadishu, Somalia. Methods . Outright, 433 COVID-19 patients were included in this study, which used a hospital-based cross-sectional design to investigate hematological alterations using the Mindray full automated hematological analyzer...
2023: Advances in Hematology
https://read.qxmd.com/read/37547186/the-success-of-treatment-free-remission-in-chronic-myeloid-leukaemia-in-clinical-practice-a-single-centre-retrospective-experience-from-south-africa
#16
JOURNAL ARTICLE
Siddeeq Hoosen, Irene Mackraj, Nadine Rapiti
INTRODUCTION: Chronic myeloid leukaemia (CML) management has evolved from a disease once considered to be incurable just over 2 decades ago to that of one of a "functional cure" as defined by the sustained molecular response on stopping tyrosine kinase inhibitor(TKI) therapy. The next goal of CML management has been treatment-free remission (TFR). The past 4 years have seen much international data on TFR attempts in CML in clinical practice. However, Africa as a continent has lagged behind the rest of the world, in keeping up with the latest trends in CML management, and so this study aims to address this gap by assessing the outcome of TFR in CML in a single centre in South Africa (SA)...
2023: Advances in Hematology
https://read.qxmd.com/read/36875183/to-measure-or-not-to-measure-direct-oral-anticoagulant-laboratory-assay-monitoring-in-clinical-practice
#17
JOURNAL ARTICLE
Tania Ahuja, Veronica Raco, Sharonlin Bhardwaj, David Green
The need for therapeutic drug monitoring of direct oral anticoagulants (DOACs) remains an area of clinical equipoise. Although routine monitoring may be unnecessary given predictable pharmacokinetics in most patients, there may be altered pharmacokinetics in those with end organ dysfunction, such as those with renal impairment, or with concomitant interacting medications, at extremes of body weight or age, or in those with thromboembolic events in atypical locations. We aimed to assess real-world practices in situations in which DOAC drug-level monitoring was used at a large academic medical center...
2023: Advances in Hematology
https://read.qxmd.com/read/36620778/outcomes-among-patients-with-mantle-cell-lymphoma-post-covalent-btk-inhibitor-therapy-in-the-united-states-a-real-world-electronic-medical-records-study
#18
JOURNAL ARTICLE
Lisa M Hess, Yongmei Chen, Paolo B Abada, Heiko Konig, Richard A Walgren
PURPOSE: There remains a lack of consensus among experts regarding the optimal therapeutic approach for Mantle cell lymphoma (MCL) after failure of covalent Bruton Tyrosine Kinase inhibitor (cBTKi)-based therapy. This study was designed to examine patient characteristics, current treatment patterns, and clinical outcomes using a real-world database to evaluate how MCL is currently managed post-cBTKi therapy in the U.S. METHODS: A large, deidentified U.S. electronic medical record (EMR) oncology database (ConcertAI) with data from January 2011 to July 2021 was utilized for this study...
2022: Advances in Hematology
https://read.qxmd.com/read/36438612/association-of-pulmonary-hypertension-and-monoclonal-gammopathy-of-undetermined-significance
#19
JOURNAL ARTICLE
Melissa A Lyle, Subir Bhatia, Eric Fenstad, Darrell Schroeder, Robert B McCully, Martha Q Lacy, Wayne Feyereisn
OBJECTIVE: To determine the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in patients with PH as well as precapillary PH. METHODS: Olmsted County residents with PH, diagnosed between 1/1/1995 and 9/30/2017, were identified, and age and sex were matched to a normal control group. The PH group and normal control group were then cross-referenced with the Mayo Clinic MGUS database. Charts were reviewed to verify MGUS and PH. Heart catheterization data were then analyzed in these patients for reference to the gold standard for diagnosis...
2022: Advances in Hematology
https://read.qxmd.com/read/36393999/the-efficacy-and-safety-of-fostamatinib-in-elderly-patients-with-immune-thrombocytopenia-a-single-center-real-world-case-series
#20
JOURNAL ARTICLE
Jessica Liu, Cyrus C Hsia
Fostamatinib is a small molecule spleen tyrosine kinase (Syk) inhibitor that was approved for the treatment of adult patients with immune thrombocytopenia (ITP) in second-line therapy. Syk inhibition prevents cytoskeletal rearrangements during phagocytosis, allowing platelet survival in ITP. However, fostamatinib treatment in elderly patients with ITP has not been well established. We performed a retrospective review of all elderly patients (age greater than or equal to 65 years) who had started on fostamatinib for the treatment of ITP at a single tertiary care centre to evaluate its efficacy and safety...
2022: Advances in Hematology
journal
journal
42335
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.